ZS Pharma shares shot up by 30% in value this week due to Swiss big-pharma Actelion admitting it might be interested in buying out the biotech for €2.2BN. This comes as ZS Pharma’s hyperkalemia candidate is set to receive FDA approval for May 2016, although this acquisition rumour could be premature given competitor Relypsa is also set to gain FDA approval.
According to Actelion, only very preliminary talks have begun regarding the acquisition everyone is gossiping about. Headquartered in Basel (Switzerland), Actelion was founded in 1998 and has already amassed a €13.7bn global market value, with a research focus on pulmonary arterial hypertension (PAH). By exploring the idea of a ZS Pharma acquisition, they aim to branch out their portfolio on hypertensive ion-based disorders to include Hyperkalemia.
Hyperkalemia describes excess serum potassium (above 5.0mEq/L) which can result from an array of conditions, such as chronic kidney disease (CKD). It can also occur as a side affect of very common renin-angiotensin-aldosterone system (RAAS inhibitors) drugs which treat heart failure related hypertension.